Lung cancer
Conditions
Interventions
Ipsilateral lung ablation combined with thoracoscopic pneumonectomy vs contralateral lung ablation combined with thoracoscopic pneumonectomy observation group:None
Ablation of the same lobe versus thoracoscopic pneumonectomy vs ablation of different lobes versus thoracoscopic pneumonectomy observation group:None
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age ranging from 18 to 75 years old (inclusive of 18 and 75), both men and women are eligible; 2. Chest high-resolution CT shows the main lesion to be 10mm or less, = 5mm and = 1.5×10^9/L, platelets >= 100×10^9/L, hemoglobin >= 9g/dL; Serum total bilirubin 1.5×ULN, the calculated creatinine clearance rate (Cockcroft-Gault formula) >= 50 mL/min.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of cancer and suspected pulmonary nodules as metastasis; 2. Those who have received any systemic anti-cancer treatment for pulmonary nodules before or after the surgery, including chemotherapy, radiotherapy, cytotoxic drug treatment, targeted drug treatment (including tyrosine kinase inhibitors or monoclonal antibodies), experimental treatment; 3. Patients with unresectable or metastatic diseases, pathological reports showing microscopic surgical margin positivity or extranodal invasion, or having residual lesions during surgery, or having suspected lesions determined by imaging after surgery; 4. Any unstable systemic diseases (including active infections, uncontrolled hypertension, unstable angina pectoris, recent-onset angina pectoris within 3 months, congestive heart failure, myocardial infarction within 6 months before enrollment, severe arrhythmias requiring drug treatment, liver, kidney or metabolic diseases); 5. History of interstitial lung disease, drug-induced interstitial lung disease, history of steroid treatment for radiation pneumonitis, or any evidence of active interstitial lung disease; 6. Patients with a clear history of neurological or mental disorders, including epilepsy or dementia; 7. Any other conditions that the investigators consider unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of Novel Tumor Cells;Spatial Distribution of Novel Tumor Cells;Classification of Lung Cancer Tumor Cell Types;Functional states and signaling pathways; | — |
Countries
China
Contacts
Public ContactHu Liao
West China Hospital of Sichuan University
Outcome results
None listed